Degenerative Disc Disease – Drugs in Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Degenerative Disc Disease – Drugs in Development, 2021, provides an overview of the Degenerative Disc Disease (Musculoskeletal Disorders) pipeline landscape.

Degenerative disc disease is refers to degeneration of intervertebral discs of the spinal column. The main symptom of degenerative disc disease is pain, which often worsens during certain types of activity. Predisposing factors include aging and injury or trauma. Treatment includes non-steroidal anti-inflammatory drugs, muscle relaxants, pain relievers and antidepressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Degenerative Disc Disease – Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 3, 2, 5, 1 and 1 respectively.

Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease (Musculoskeletal Disorders).

– The pipeline guide reviews pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Degenerative Disc Disease (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Amplicore Inc

AnGes Inc

Angitia Biopharmaceuticals

Bone Therapeutics SA

CHA Biotech Co Ltd

DiscGenics Inc

FibroGenesis LLC

Histogen Inc

Kolon TissueGene Inc

Locate Bio Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Degenerative Disc Disease - Overview

Degenerative Disc Disease - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Degenerative Disc Disease - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Degenerative Disc Disease - Companies Involved in Therapeutics Development

Amplicore Inc

AnGes Inc

Angitia Biopharmaceuticals

Bone Therapeutics SA

CHA Biotech Co Ltd

DiscGenics Inc

FibroGenesis LLC

Histogen Inc

Kolon TissueGene Inc

Locate Bio Ltd

Notogen Inc

Stayble Therapeutics AB

Techfields Pharma Co Ltd

U.S. Stem Cell Inc

Xalud Therapeutics Inc

Yuhan Corp

Degenerative Disc Disease - Drug Profiles

AdipoCell - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGA-111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALLOB - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-2101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-0101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-0103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBAC-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBAC-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CybroCell - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HST-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NTG-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STA-363 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy 1 for Degenerative Disc Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Degenerative Disc Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Degenerative Disc Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-D - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

X-0002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XT-150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YH-14618 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Degenerative Disc Disease - Dormant Projects

Degenerative Disc Disease - Product Development Milestones

Featured News & Press Releases

May 14, 2020: Histogen publishes preclinical data on its HST 004 spinal disc program

Nov 14, 2018: Therapeutic potential of NTG-101, a single dose injectable treatment for Degenerative Disc Disease, demonstrated in preclinical large animal study published in Nature Publishing Group's "Scientific Reports"

Mar 20, 2018: USRM Chief Science Officer to Present at Paleo f(x) Ancestral Healing Conference in Austin, Texas

Feb 28, 2018: USRM Chief Science Officer to Present at Academy of Regenerative Practices Conference

Jan 15, 2018: USRM Reaches Key Sales Milestone of Proprietary Adipocell Product

Nov 28, 2017: Degenerative Disc Patients Significantly Improve With USRM’s Adipocell

Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study

Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial

May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB® Phase IIA spinal fusion study

Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the ‘Clinical Applications of Stem Cells’ Conference

Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial

Nov 17, 2014: Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease

Sep 15, 2014: Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion

Mar 26, 2014: Bioheart Announces Clinical Study for Degenerative Disc Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Degenerative Disc Disease, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Degenerative Disc Disease – Pipeline by Amplicore Inc, 2021

Degenerative Disc Disease – Pipeline by AnGes Inc, 2021

Degenerative Disc Disease – Pipeline by Angitia Biopharmaceuticals, 2021

Degenerative Disc Disease – Pipeline by Bone Therapeutics SA, 2021

Degenerative Disc Disease – Pipeline by CHA Biotech Co Ltd, 2021

Degenerative Disc Disease – Pipeline by DiscGenics Inc, 2021

Degenerative Disc Disease – Pipeline by FibroGenesis LLC, 2021

Degenerative Disc Disease – Pipeline by Histogen Inc, 2021

Degenerative Disc Disease – Pipeline by Kolon TissueGene Inc, 2021

Degenerative Disc Disease – Pipeline by Locate Bio Ltd, 2021

Degenerative Disc Disease – Pipeline by Notogen Inc, 2021

Degenerative Disc Disease – Pipeline by Stayble Therapeutics AB, 2021

Degenerative Disc Disease – Pipeline by Techfields Pharma Co Ltd, 2021

Degenerative Disc Disease – Pipeline by U.S. Stem Cell Inc, 2021

Degenerative Disc Disease – Pipeline by Xalud Therapeutics Inc, 2021

Degenerative Disc Disease – Pipeline by Yuhan Corp, 2021

Degenerative Disc Disease – Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development for Degenerative Disc Disease, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports